RAMUCIRUMAB IN A COMBINATION WITH IRINOTECAN-BASED TWO-COMPONENT THERAPY REGIMEN AS THE SECOND LINE FOR THE TREATMENT OF DISSEMINATED GASTRIC CANCER. CASE REPORT


DOI: https://dx.doi.org/10.18565/pharmateca.2018.7.102-104

T.A. Titova, N.S. Besova, V.A. Gorbunova, A.A. Fedenko, O.A. Malikhova

N.N. Blokhin National Medical Research Center of Oncology, Moscow
Background. Gastric cancer is one of the most widespread malignant tumors in the world, the treatment of which is receiving increasing attention every year. Description of the clinical case. The article presents a clinical case of successful use of ramucirumab in combination with FOLFIRI as the 2nd line of therapy for a patient with disseminated gastric adenocarcinoma.

About the Autors


Corresponding author: N.S. Besova – PhD in Medical Sciences, Senior Researcher at the Department of Chemotherapy N.N. Blokhin NMRC of Oncology, Moscow; e-mail besovans@mail.ru, ORCID: https://orcid.org/0000-0002-1693-0523


Similar Articles


Бионика Медиа